1-bromo-2-(bromomethyl)-6-fluoronaphthalene | 301822-83-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: 1-bromo-2-(bromomethyl)-6-fluoronaphthalene
• CAS: 301822-83-3
• 化学式: C₁₁H₇Br₂F
• 分子量: 317.983
• InChiKey: HKVCFWDGTSUHCI-UHFFFAOYSA-N

物化性质

• 沸点：
  366.6±27.0 °C(Predicted)
• 密度：
  1.833±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.5
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  1-bromo-2-(bromomethyl)-6-fluoronaphthalene 在 吡啶 、 氯化亚砜 、 盐酸羟胺 、 sodium methylate 作用下， 以 甲醇 、 二氯甲烷 、 水 、 二甲基亚砜 、 乙腈 为溶剂， 反应 20.92h， 生成 4-[(1-bromo-6-fluoronaphthalen-2-yl)methyl]-5H-1,2,3,5-oxathiadiazole 2-oxide
  参考文献：
  名称：

  Antihyperglycemic activity of novel naphthalenylmethyl-3H-1,2,3,5-oxathiadiazole 2-oxides

  摘要：

  A series of naphthalenyl 3H-1,2,3,5-oxathiadiazole 2-oxides was prepared and tested for antihyperglycemic activity in the db/db mouse, a model for type 2 (non-insulin dependent) diabetes mellitus. Substitution at the 1-, 5-, or 8-positions of the naphthalene ring with a halogen was found to be beneficial to antihyperglycemic activity. 4-[(5-Chloronaphthalen-2-yl)methyl]-3H-1,2,3,5-oxathiadiazole 2-oxide (45), one of the most potent compounds in this series, was selected for further pharmacological evaluation.

  DOI：

  10.1021/jm00069a006
• 作为产物：
  描述：

  对氟苯乙酰氯 在 N-溴代丁二酰亚胺(NBS) 、 三氯化铝 、 三苯基甲醇 、 偶氮二异丁腈 、 溴 、 四氯化钛 、 溶剂黄146 、 三氟乙酸 作用下， 以 四氢呋喃 、 四氯化碳 、 二氯甲烷 为溶剂， 反应 53.75h， 生成 1-bromo-2-(bromomethyl)-6-fluoronaphthalene
  参考文献：
  名称：

  Antihyperglycemic activity of novel naphthalenylmethyl-3H-1,2,3,5-oxathiadiazole 2-oxides

  摘要：

  A series of naphthalenyl 3H-1,2,3,5-oxathiadiazole 2-oxides was prepared and tested for antihyperglycemic activity in the db/db mouse, a model for type 2 (non-insulin dependent) diabetes mellitus. Substitution at the 1-, 5-, or 8-positions of the naphthalene ring with a halogen was found to be beneficial to antihyperglycemic activity. 4-[(5-Chloronaphthalen-2-yl)methyl]-3H-1,2,3,5-oxathiadiazole 2-oxide (45), one of the most potent compounds in this series, was selected for further pharmacological evaluation.

  DOI：

  10.1021/jm00069a006

文献信息

• [EN] RESPIRATORY SYNCYTIAL VIRUS INHIBITORS<br/>[FR] INHIBITEURS DU VIRUS RESPIRATOIRE SYNCYTIAL
  申请人：MEDIVIR AB

  公开号：WO2018038667A1

  公开（公告）日：2018-03-01

  Compounds of Formula (I): wherein W is NR1A or CR1BR1B; Z is N or CH; R1A is C1-C3alkyl, C1-C3haloalkyl C3-C4cycloalkyl or phenyl wherein cycloalkyl or phenyl is optionally mono-, di- or tri-substituted with substituents each independently selected from C1- C3alkyl, halo, amino and C1-C3alkoxy; the two R1B together with the carbon atom to which they are attached combine and form C3-C6cycloalkyl or heterocyclyl, wherein the cycloalkyl is substituent with C(=O)OR1C, NHC(=O)OR1C or NHS(=O)2R1C, and the heterocyclyl is substituent with C(=O)R1C, C(=O)OR1C, S(=O)2 R1C, C(=O)NH2 or C(=O)NR1CR1C'; n is 0, 1 or 2; n, q, R1C, R1C', R2 and R3 are as defined herein, their use as inhibitors of RSV and related aspects.

  式(I)的化合物：其中W为NR1A或CR1BR1B；Z为N或CH；R1A为C1-C3烷基，C1-C3卤代烷基，C3-C4环烷基或苯基，其中环烷基或苯基可选择性地单取代，二取代或三取代，取代基分别独立地选自C1-C3烷基，卤素，氨基和C1-C3甲氧基；两个R1B与它们连接的碳原子结合形成C3-C6环烷基或杂环烷基，其中环烷基取代为C(=O)OR1C，NHC(=O)OR1C或NHS(=O)2R1C，而杂环烷基取代为C(=O)R1C，C(=O)OR1C，S(=O)2R1C，C(=O)NH2或C(=O)NR1CR1C'；n为0, 1或2；n，q，R1C，R1C'，R2和R3如本文所定义，它们作为RSV的抑制剂及相关方面的用途。
• WO2006/64351
  申请人：——

  公开号：——

  公开（公告）日：——
• Design and optimization of selective serotonin re-uptake inhibitors with high synthetic accessibility Part 1
  作者：Mark Andrews、Alan Brown、Jean-Yves Chiva、David Fradet、David Gordon、Mark Lansdell、Malcolm MacKenny

  DOI：10.1016/j.bmcl.2009.02.054

  日期：2009.4

  The reported selective serotonin Re-uptake Inhibitor Litoxetine was used as the starting point in the design of a range of potential SSRIs with high ease of synthetic accessibility. Preparation and subsequent optimization yielded a range of potent and highly selective SSRIs. (C) 2009 Elsevier Ltd. All rights reserved.
• N-PYRROLIDIN-3-YL-AMIDE DERIVATIVES AS SEROTONIN AND NORADRENALIN RE-UPTAKE INHIBITORS
  申请人：Pfizer Limited

  公开号：EP1828122A2

  公开（公告）日：2007-09-05
• [EN] NOVEL COMPOUNDS<br/>[FR] NOUVEAUX COMPOSES
  申请人：PFIZER LTD

  公开号：WO2006064351A2

  公开（公告）日：2006-06-22

  [EN] A compound of Formula (I) and pharmaceutically and/or veterinarily acceptable derivatives thereof, wherein: R¹ is H, C_1-6alkyl, -C(A)Y, C_3-8cycloalkyl, aryl, het, aryl-C_1-4alkyl or het-C_l-4alkyl, wherein the cycloalkyl, aryl or het groups are optionally substituted; A is S or O; Y is H, C_1-6alkyl, aryl, het, aryl-C_1-4alkyl or het­-C_1-4alkyl; aryl is independently selected from phenyl, naphthyl, anthracyl or phenanthryl; het is independently selected from an aromatic or non-aromatic 4-, 5- or 6- membered heterocycle which contains at least one N, O or S heteroatom, optionally fused to a 5- or 6- membered carbocyclic group or a second 4-, 5- or 6-membered heterocycle which contains at least one N, O or S heteroatom; R² is aryl¹ or het¹, each optionally substituted; aryl¹ is independently selected from phenyl, naphthyl, anthracyl, phenanthryl, or indanyl; het¹ is an aromatic 5 to 10 membered heterocyclic ring system which contains at least one N, O or S heteroatom, optionally containing an aryl group; R³ is H, C_1-8alkyl, C_3-8cycloalkyl, C_3-8cycloalkyl-C_1-6alkyl, C_1-8alkylSC_1-8alkyl, het³, or het³-C_1-4alkyl, wherein the alkyl, cycloalkyl and het³ groups are each optionally substituted; het³ is a non-aromatic 4-, 5- or 6- membered heterocycle which contains at least one N, O or S heteroatom, optionally fused to a 5- or 6- membered carbocyclic group or a second 4-, 5- or 6-membered heterocycle which contains at least one N, O or S heteroatom; or R³ is (CH₂)_a ^,K
  [FR] L'invention porte sur un composé représenté par la formule (I) et sur ses produits dérivés acceptables sur le plan pharmaceutique et/ou vétérinaire dans laquelle R¹ est H, C₁-₆alkyl, -C(A)Y, C₃.₈cycloalkyl, aryl, het, aryl-C₁-,alkyl ou het-C_l.₄alkyl, les groupes cycloalkyle, aryle ou het étant éventuellement substitués; A est S ou O; Y est H, C₁-₆alkyl, aryl, het, aryl-C_I.₄alkyl ou het-C₁_₄alkyl; aryle est sélectionné indépendamment parmi phényle, naphthyle, anthracyle ou phénanthryle; het est sélectionné indépendamment parmi un hétérocycle aromatique ou non aromatique à 4, 5 ou 6 chaînons qui contient au moins un hétéroatome N, O ou S éventuellement fusionné à un groupe carbocyclique à 5 ou 6 chaînons ou un deuxième hétérocycle à 4, 5 ou 6 chaînons qui contient au moins un hétéroatome N, O ou S. R² est aryl¹ ou het¹, chacun éventuellement substitué; aryl¹ est sélectionné indépendamment parmi phényle, naphthyle, anthracyle, phénanthryle ou indanyle; het¹ est un système de noyau hétérocyclique aromatique de 5 à 10 chaînons qui contient au moins un hétéroatome N, O or S, contenant éventuellement un groupe aryle; R³ est H, C₁_₈alkyl, C₃_₈cycloalkyl, C₃- ₈cycloalkyl-C₁-6alkyl, C₁-₃alkylSC₁-₈alkyl, het³ ou het³-C₁.₄alkyl, les groupes alkyle, cycloalkyle et het³ étant chacun éventuellement substitués, het³ est un hétérocycle non aromatique à 4, 5 ou 6 chaînons qui contient au moins un hétéroatome N, O ou S, éventuellement fusionné à un groupe carbocyclique à 5 ou 6 chaînons ou un deuxième hétérocycle à 4, 5 ou 6 chaînons qui contient au moins un hétéroatome N, O ou S ; ou R³ est (CH₂)_a ^,K